NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/19/2023
Back to search
Official data from USPTO
TEVA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
12/19/2023
Trademark type
Combined
Nice classes
5
Filing date
10/20/2020
Registration date
12/19/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/19/2023
Last transaction
12/19/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
11/01/2013
First use in commerce
11/01/2013
Drawing code
3
Owner type
99
Owner location
Tel Aviv, IL
Examiner
HOWELL,MATTHEW PATTERSON
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of two curved band designs that begins at the bottom center of an outlined rectangle and rise up toward the upper right hand corner of the rectangle. In the center of the curved band design is a large circle with an outline around the left side. In the bottom right hand corner is the word ''TEVA'' in lower case letters. The ''V'' in the word ''TEVA'' is formed by 2 leaf shapes. The entire mark is outlined by a thin line in the shape of a rectangle.
Holders and representatives
Holders
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Representatives
Laurence Rickles
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that supportencourage and promote bone strength; Pharmaceutical preparations that supportencourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparationsinjectable contraceptives; Pharmaceutical preparationscontraceptive preparations; Pharmaceutical preparationsfertility enhancement preparations; Pharmaceutical preparationshormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system
Publications
History of USPTO decisions and trademark events.
41 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/19/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/14/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/13/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/13/2023
IUAF
USE AMENDMENT FILED
11/08/2023
EISU
TEAS STATEMENT OF USE RECEIVED
11/08/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/02/2023
EX4G
SOU EXTENSION 4 GRANTED
04/28/2023
EXT4
SOU EXTENSION 4 FILED
04/28/2023
EEXT
SOU TEAS EXTENSION RECEIVED
04/28/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/04/2022
EX3G
SOU EXTENSION 3 GRANTED
11/02/2022
EXT3
SOU EXTENSION 3 FILED
11/02/2022
EEXT
SOU TEAS EXTENSION RECEIVED
11/02/2022
EX3M
SOU EXTENSION 3 DENIAL LETTER PREPARED
05/17/2022
EX3D
SOU EXTENSION 3 DENIAL LETTER PREPARED
05/17/2022
EXT3
SOU EXTENSION 3 FILED
05/17/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/17/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/11/2022
EEXT
SOU TEAS EXTENSION RECEIVED
05/10/2022
EX2G
SOU EXTENSION 2 GRANTED
05/09/2022
EXT2
SOU EXTENSION 2 FILED
05/09/2022
EEXT
SOU TEAS EXTENSION RECEIVED
05/09/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/09/2021
EX1G
SOU EXTENSION 1 GRANTED
11/05/2021
EXT1
SOU EXTENSION 1 FILED
11/05/2021
EEXT
SOU TEAS EXTENSION RECEIVED
11/05/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/11/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/16/2021
PUBO
PUBLISHED FOR OPPOSITION
03/16/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/24/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/09/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
02/09/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/09/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
02/09/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/09/2021
DOCK
ASSIGNED TO EXAMINER
02/05/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/09/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/08/2020
NWAP
NEW APPLICATION ENTERED
10/23/2020
Continuous trademark protection
Get notified about every new filing that threatens TEVA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.